The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Svetlana Semenova, Athina Markou

Abstract

Based on phenomenological similarities between anhedonia (reward deficits) associated with drug withdrawal and the negative symptoms of schizophrenia, we showed previously that the atypical antipsychotic clozapine attenuated reward deficits associated with psychostimulant withdrawal. Antagonism of alpha(2) adrenergic and 5-HT(2A) receptors may contribute to these effects of clozapine. We investigated here whether blockade of alpha(2) or 5-HT(2A) receptors by idazoxan and M100907, respectively, would reverse anhedonic aspects of psychostimulant withdrawal. Idazoxan treatment facilitated recovery from spontaneous nicotine, but not amphetamine, withdrawal by attenuating reward deficits and increase the number of somatic signs. Thus, alpha(2) adrenoceptor blockade may have beneficial effects against nicotine withdrawal and may be involved in the effects of clozapine previously observed. M100907 worsened the anhedonia associated with nicotine and amphetamine withdrawal, suggesting that monotherapy with M100907 may exacerbate the expression of the negative symptoms of schizophrenia or nicotine withdrawal symptoms in people, including schizophrenia patients, attempting to quit smoking.

References

Mar 1, 1979·Archives of General Psychiatry·C KornetskyJ O Jacobson
Jan 1, 1976·Psychopharmacologia·N J Leith, R J Barrett
Feb 1, 1992·Naunyn-Schmiedeberg's Archives of Pharmacology·R Tao, S Hjorth
May 1, 1992·Naunyn-Schmiedeberg's Archives of Pharmacology·I M Coupar
Jan 1, 1992·Psychopharmacology·A MarkouG F Koob
Nov 1, 1992·Pharmacology, Biochemistry, and Behavior·D H MalinO B Wilson
Jul 8, 1992·Annals of the New York Academy of Sciences·R A WiseW Trojniar
Mar 14, 1991·The New England Journal of Medicine·R J Baldessarini, F R Frankenburg
Jan 25, 1991·European Journal of Pharmacology·J C GarrattC A Marsden
Aug 15, 1991·The New England Journal of Medicine·L J FriedmanM Sved
Jan 1, 1989·Neuroscience and Biobehavioral Reviews·A G PhillipsH C Fibiger
May 20, 1988·JAMA : the Journal of the American Medical Association·A H GlassmanL S Covey
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jul 1, 1987·Archives of General Psychiatry·D R Weinberger
Mar 1, 1983·British Journal of Pharmacology·J C DoxeyC F Smith
Jul 12, 1995·Annals of the New York Academy of Sciences·A Parini
Jul 12, 1995·Annals of the New York Academy of Sciences·D J NuttL Lione
Jan 1, 1994·Clinical Pharmacology and Therapeutics·S GourlayJ McNeil
Nov 1, 1995·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·N BrunelloG Racagni
May 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·R E LitmanD Pickar
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Mar 1, 1996·Pharmacology, Biochemistry, and Behavior·Y K FungY S Lau
Jan 1, 1997·Journal of Psychopharmacology·D J NuttA L Hudson
Oct 23, 1997·The New England Journal of Medicine·R D HurtP M Sullivan
May 7, 1998·European Journal of Pharmacology·M MatsumotoH Saito
May 20, 1998·Nature·M P Epping-JordanA Markou
Oct 20, 1998·Archives of Internal Medicine·A V ProchazkaD Lofaso
Mar 4, 1999·The New England Journal of Medicine·D E JorenbyT B Baker
Mar 24, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G B VartyM A Geyer

❮ Previous
Next ❯

Citations

Mar 29, 2011·Annual Review of Neuroscience·Mariella De Biasi, John A Dani
Jan 26, 2011·European Journal of Pharmacology·Styliani VlachouAthina Markou
Jul 26, 2011·Biochemical Pharmacology·Michael Paolini, Mariella De Biasi
Apr 29, 2014·Behavioural Brain Research·Christian P Müller, Judith R Homberg
Feb 23, 2016·Veterinary Medicine and Science·J Mark Craig
Apr 23, 2013·Fundamental & Clinical Pharmacology·Manish Manohar AglaweNandkishor Ramdas Kotagale
Apr 24, 2021·Journal of Psychopharmacology·Ranjithkumar ChellianAdriaan W Bruijnzeel
Jan 17, 2012·ACS Chemical Neuroscience·Matthew J ShashackScott R Gilbertson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Journal of Pharmacology and Experimental Therapeutics
M I DamajB R Martin
Pharmacology, Biochemistry, and Behavior
Paul J Kenny, Athina Markou
Pharmacology, Biochemistry, and Behavior
D H MalinO B Wilson
© 2021 Meta ULC. All rights reserved